Skip to content

Reviva Pharmaceuticals Holdings, Inc.: 10-Q filed 2025-08-14

What Reviva Pharmaceuticals Holdings, Inc. reported in its quarterly report filed 2025-08-14 (fiscal Q2 2025): 28 published measures, 84 facts as tagged in accession 0001437749-25-026967.

This filing

Form
10-Q (quarterly report)
Filed
2025-08-14
Fiscal period
fiscal Q2 2025
Accession
0001437749-25-026967 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Reviva Pharmaceuticals Holdings, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-06-3011,634,846USD
At 2024-12-3115,503,088USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-06-3012,093,993USD
At 2024-12-3114,690,516USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-06-30-459,147USD
At 2025-03-31-4,460,024USD
At 2024-12-31812,572USD
At 2024-06-30-6,041,522USD
At 2024-03-31-1,345,817USD
At 2023-12-315,718,716USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-06-3010,363,714USD
At 2024-12-3113,476,331USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-6,053,610USD91
2025-01-01 to 2025-06-30-12,486,450USD181
2024-04-01 to 2024-06-30-7,859,919USD91
2024-01-01 to 2024-06-30-15,293,527USD182

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-01-01 to 2025-06-30-13,206,946USD181
2024-01-01 to 2024-06-30-20,201,997USD182

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-01-01 to 2025-06-3010,094,329USD181
2024-01-01 to 2024-06-303,012,721USD182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-06-30-176,759,500USD
At 2024-12-31-164,273,050USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-04-01 to 2025-06-3049,847,872shares91
2025-01-01 to 2025-06-3049,249,430shares181
2024-04-01 to 2024-06-3030,555,012shares91
2024-01-01 to 2024-06-3030,221,168shares182

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-0.12USD/shares91
2025-01-01 to 2025-06-30-0.25USD/shares181
2024-04-01 to 2024-06-30-0.26USD/shares91
2024-01-01 to 2024-06-30-0.51USD/shares182

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2025-04-01 to 2025-06-307,954USD91
2025-01-01 to 2025-06-3013,167USD181
2024-04-01 to 2024-06-307,385USD91
2024-01-01 to 2024-06-3014,781USD182

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-01-01 to 2025-06-301,314,396USD181
2024-01-01 to 2024-06-30728,068USD182

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-6,072,982USD91
2025-01-01 to 2025-06-30-12,611,149USD181
2024-04-01 to 2024-06-30-8,129,643USD91
2024-01-01 to 2024-06-30-16,051,749USD182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-06-3010,815,125USD
At 2024-12-3114,683,367USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-06-3012,077,303USD
At 2024-12-3114,601,506USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2025-06-304,968,688USD
At 2024-12-316,283,430USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-04-01 to 2025-06-306,072,982USD91
2025-01-01 to 2025-06-3012,611,149USD181
2024-04-01 to 2024-06-308,129,643USD91
2024-01-01 to 2024-06-3016,051,749USD182

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-04-01 to 2025-06-303,724,755USD91
2025-01-01 to 2025-06-307,838,292USD181
2024-04-01 to 2024-06-305,584,347USD91
2024-01-01 to 2024-06-3011,368,212USD182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-06-3068,003,613shares
At 2024-12-3146,579,199shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-06-30176,293,553USD
At 2024-12-31165,080,964USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2025-06-30346,964USD
At 2024-12-31666,435USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-6,045,656USD91
2025-01-01 to 2025-06-30-12,473,283USD181
2024-04-01 to 2024-06-30-7,852,534USD91
2024-01-01 to 2024-06-30-15,278,746USD182

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2025-04-01 to 2025-06-302,348,227USD91
2025-01-01 to 2025-06-304,772,857USD181
2024-04-01 to 2024-06-302,545,296USD91
2024-01-01 to 2024-06-304,683,537USD182

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2025-04-01 to 2025-06-304,797USD91
2025-01-01 to 2025-06-3016,417USD181
2024-04-01 to 2024-06-305,153USD91
2024-01-01 to 2024-06-308,640USD182

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-1,850USD91
2025-01-01 to 2025-06-30-26,995USD181
2024-04-01 to 2024-06-30-5,621USD91
2024-01-01 to 2024-06-30-135,515USD182

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2025-04-01 to 2025-06-3027,326USD91
2025-01-01 to 2025-06-30137,866USD181
2024-04-01 to 2024-06-30277,109USD91
2024-01-01 to 2024-06-30773,003USD182

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2025-01-01 to 2025-06-3014,224USD181
2024-01-01 to 2024-06-308,640USD182

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-06-30-1,535,859USD181
2024-01-01 to 2024-06-30844,252USD182

Inspect the source

Entity
Reviva Pharmaceuticals Holdings, Inc. / CIK 0001742927
Captured
2026-09-19T11:20:56.685Z
SEC response SHA-256
26f740ff1a169faebcba46f28197dc15a1be7bab2feb9b4952e7b7f15df066e6

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001742927.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))